Dan O’Day’s to-do list for Gilead: Re­cruit a Kite CEO, press the ped­al on next-gen cell ther­a­pies and start ...

7 years ago
People
R&D

Tes­sa show­cas­es pre­clin­i­cal promise of 'all-in-one' add-on to its can­cer cell ther­a­py, in march to the clin­ic

7 years ago
Discovery
Cell/Gene Tx

Weeks af­ter a Pfiz­er/Mer­ck KGaA break­down, Clo­vis gam­bles on a $175M loan to fin­ish a glob­al PhI­II PARP/PD-1 com­bo ...

7 years ago
Financing
R&D

Cel­gene part­ners on Phase 0 can­cer drug stud­ies; FDA lifts clin­i­cal hold on Xen­cor's bis­pe­cif­ic

7 years ago
News Briefing

As­traZeneca bets cau­tious­ly on on­colyt­ic virus dis­cov­ery pro­gram, out­lin­ing $13M deal with Trans­gene

7 years ago
R&D
Discovery

Go­ing glob­al, Take­da opens up 165,000-square-foot R&D fa­cil­i­ty in San Diego

7 years ago
R&D

Ter­ry Rosen is look­ing to leave the thun­der­ing herd and blaze a new trail in PD-1 R&D

7 years ago
People
R&D

Sanofi's con­tro­ver­sial dengue vac­cine wins FDA ap­proval, with a raft of caveats

7 years ago
Pharma

The BC­MA fren­zy: Track­ing the 37 drugs around the world rac­ing to over­take blue­bird bio and Cel­gene

7 years ago
R&D

Mi­cro­bio­me play­er uBio­me puts founders on leave, in­ter­im CEO promis­es to as­sist in fed­er­al probe

7 years ago
People

Why did GSK kill two vac­cine R&D pro­grams? CEO Em­ma Walm­s­ley is glad you asked

7 years ago
R&D

Ab­b­Vie nabs pe­di­atric OK for hep C drug Mavyret; Glen­mark launch­es cheap­er SGLT2 in­hibitor in In­dia

7 years ago
News Briefing

Al­ler­gan CEO Saun­ders hangs on to chair­man's ti­tle, win­ning share­hold­er sup­port — but not by a big enough mar­gin to ...

7 years ago
People

Man­u­fac­tur­ing is­sues hob­ble Heron's quest to mar­ket its long-act­ing non-opi­oid painkiller

7 years ago
Pharma

173 to 1: Bris­tol-My­ers chief Caforio picked up a $19.4M com­pen­sa­tion deal af­ter lead­ing the charge for $74B Cel­gene ...

7 years ago
People

Man­u­fac­tur­ing con­cerns spike Nabri­va’s plans to launch its first an­tibi­ot­ic — for now

7 years ago
R&D

Gilead los­es yet an­oth­er ex­ec­u­tive as CFO Wash­ing­ton joins ex­o­dus, jump­ing to Al­pha­bet board

7 years ago
People

'So­phis­ti­cat­ed' cy­berthieves hacked in­to Charles Riv­er Labs and made off with clients’ drug da­ta

7 years ago
Outsourcing

FDA adds boxed warn­ings to in­som­nia med­i­cines fol­low­ing in­juries, deaths

7 years ago
Pharma

Roche spins out Nim­ble Ther­a­peu­tics to cap­i­tal­ize on pep­tide drug dis­cov­ery, with $10M sup­port from Tele­graph Hill ...

7 years ago
Startups

Share price blitzed, an­a­lysts in an up­roar af­ter lead PhI­II drug im­plodes — and Bio­gen un­veils a $2.5M raise for ...

7 years ago
People

The right mix mat­ters in bio­phar­ma lead­er­ship

7 years ago
Biotech Voices

As Mer­ck cel­e­brates ris­ing flow of Keytru­da cash, ex­ecs plot fa­cil­i­ty shut­downs, lay­offs in $1.2B re­or­ga­ni­za­tion

7 years ago
Pharma

As­traZeneca teams with Benev­o­len­tAI on dis­cov­ery, re­search; Cam­bridge spin­out rais­es seed cash for pro­tein ...

7 years ago
News Briefing
First page Previous page 953954955956957958959 Next page Last page
A service from the Financial Times